Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic cytotoxic T lymphocytes + aldesleukin
- Development stage
- Unknown
- Lead developer
- University of Colorado Anschutz Medical Campus
- Modality
- Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intracavitary
01
Overview
An experimental adoptive cellular immunotherapy consisting of allogeneic cytotoxic T lymphocytes (CTLs) and recombinant human interleukin-2 (aldesleukin). Developed by researchers at the University of Colorado, Denver, this therapy is designed to treat recurrent primary brain tumors, including glioblastoma and anaplastic astrocytoma. The CTLs are derived from MHC-disparate donors and sensitized against the patient's major histocompatibility complex (MHC) proteins to selectively target and eliminate glioma cells. The treatment is administered directly into the tumor cavity (intracavitary) following surgical resection, with IL-2 provided to enhance the survival and activity of the infused T cells.
- Other names
- intracavitary allogeneic cytotoxic T lymphocytesallogeneic CTLsallogeneic cytotoxic T lymphocytes-University of Colorado, Denver-recurrent primary brain tumor
02
Targets
TCR (T cell antigen receptor complex)IL-2R (Interleukin-2/interleukin-15 receptor complex)pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on allogeneic cytotoxic T lymphocytes + aldesleukin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic cytotoxic T lymphocytes + aldesleukin.